|
||
| |||||||
| An
introduction to the key CNS Disorders
Alzheimer's
Disease: Over
the last 3 years, the value of the Alzheimer's disease market has grown by an
average of 19% per year. Growth has been driven by increasing availability and
reimbursement of Alzheimer's drugs. There are considerable opportunities within
these markets due to an ageing population and the high unmet clinical need,
particularly within the late stage of disease. In addition, research over the
last 20 years has increased our understanding of the underlying mechani Nootropic
drugs or anti-Alzheimer's drugs are one of the largest segments of the
neurodegenerative market and accounted for 33% of global sales (US$2.6 billion
in 2003 and equivalent to 4% of global CNS drug sales). The market for drugs to
treat Alzheimer's disease has grown steadily since the launch of Aricept
in 1996 and experienced 21% growth year-on-year in 2003. Whilst the Further
reading:
************************************ Multiple
Sclerosis:
It is estimated that over 350,000 Americans (approximately 1 in 1,000 aged over
30 years) live with multiple sclerosis (MS) and approximately 3 million live
with it worldwide. However, the prevalence may be higher because of the
uncertainty in diagnosing the condition. Women are twice as susceptible as men
and it is more common in people in northern latitudes over the age of 18 years.
In addition, siblings of an individual with multiple sclerosis have a higher
chance of developing the disease. The incidence of multiple sclerosis varies
throughout the world, although there is a significantly higher incidence of the
disease found in the Northern Hemisphere. Multiple sclerosis is the most common
cause of neurological disability in young adults in the Approximately
56% of multiple sclerosis global sales were derived from the Further
reading:
************************************ Attention
Deficit Hyperactivity Disorder (ADHD): The
value of the ADHD market was US$1.7 billion in 2003 and it is now the 11th
largest segment of the CNS market by sales and one of the fastest growing (+33%
year-on-year). Global sales of ADHD are forecast to reach US$3 billion by 2010.
This will be due to greater penetration in the treatment of new patients
particularly adult ADHD, improvements in patient compliance due to the launch of
new formulations, new non-schedule II drugs and the development of novel classes
of drugs in late-stage clinical trials. There has been a significant increase in
ADHD diagnosis and prescription of medicine since the early 1990s due to wider
understanding of the condition in the mental health community, increased use of
medication and healthcare coverage and the launch of ADHD specific drugs (from
2000 onwards). ADHD is one of the most common psychiatric disorders of childhood
and approximately 50% to 70% of children with ADHD will continue to experience
symptoms into adulthood. In 2000, it was estimated that 4-5 million individuals
(mainly children) were diagnosed with ADHD of whom,
75-85% were treated with psychostimulants. Over 8
million adults in the Approximately
97% of ADHD global sales were derived from the Further
reading: ************************************ Focusing
on Insomnia: The
insomnia market is on the verge of considerable growth due to the launch of new
formulations of leading drugs, new classes of drugs with improved side-effect
profiles and patient dynamics - an ageing patient population.
New formulations are reaching the market and leading brand products face
competition from generics and from the new GABA-A receptor agonists: Estorra
(Sepracor) to be launched in late 2004, Indiplon
( Approximately
US$2.5 billion is currently spent on hypnotics and sedatives in the treatment of
insomnia the 8th largest segment of CNS drug sales. The global market for
insomnia drug sales is unevenly distributed. In 2003, the Further
reading: ************************************ Depression:
The
depression market is the largest segment of the CNS market with global sales of
US$15.5 billion in 2003, and has grown by 12% year-on-year. This is a mature
market with a number of the leading brands facing patent expiration in the next
6 years. The dynamics of the marketplace are changing as new classes of drugs
such as the selective noradrenaline reuptake
inhibitor, Cymbalta (Eli Lilly), and new
formulations of drugs such as the 5-HT1A antagonist, Wellbutrin
XL (GSK), are launched. It is estimated that depression affects over 18.8
million The
global market for antidepressants is unevenly distributed. In 2003, the Further
reading:
************************************ Focusing
on Neuropathic Pain: Pain
products generated global sales of nearly US$40 billion in 2003 (including anaesthetics
and antimigraine agents) and this is expected to
double by 2010.
Pain is associated with a broad range of diseases and is often poorly diagnosed
and treated. There has been tremendous research activity into the treatment of
pain and many types of pain remain relatively unexplored. Approximately 26
million patients worldwide (10 million in the It
is difficult to determine the exact amount spent on the management of pain as
several classes of drug are used "off-label" in the treatment of pain
such as antidepressants and anti-epileptics. We anticipate that by 2010, sales
of neuropathic pain drugs will double to US$5.5 billion. Sales will be driven by
the launch of novel therapeutic drugs that specifically target subsets of
neuropathic pain associated with: HIV infection, shingles, diabetes, immune
disorders and toxic neuropathies (for example following treatment with
chemotherapeutics). These include the development of antidepressants (Cymbalta),
antiepileptic agents (Lyrica and Prialt)
glutamate antagonists (Namenda, Lamictal
and CNS 5161) and the cannabinoid agonist (Sativex). Further
reading:
To subscribe to DailyUpdates - click here! LeadDiscovery Reports - click here |
|
| ||||||||